Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-10 01:38:52 EDT

Explore

PostsPeople
LatestRanked
@midgardfinance.comOct 1, 2026, 3:30 PM

💉 #pharma #EASD2026

🇺🇸 $LLY #eloralintide added 8.5 points of weight loss to tirzepatide in type 2 diabetes: 23.3% vs 14.8%, 48 wk.

🇩🇰 $NOVO #CagriSema: 4.0 added to semaglutide, 14.2% vs 10.2%, 68 wk. One-molecule #zenagamtide: 14.6%, 36 wk.

Separate trials.

midgardfinance.com/diabetes/

Chart titled "Amylin added 8.5 points to tirzepatide, 4.0 to semaglutide". Three rows, each a separate trial in adults with type 2 diabetes, showing the average weight loss at the top dose as estimated for people staying on treatment. Top row, Lilly, two molecules, phase 2b, 48 weeks: a grey point for tirzepatide 15 mg alone at 14.8 per cent joined to a red point for the same dose with eloralintide 9 mg at 23.3 per cent. Middle row, Novo, two molecules, the REIMAGINE 2 trial, phase 3, 68 weeks: a grey point for semaglutide 2.4 mg alone at 10.2 per cent joined to a blue point for the same dose with cagrilintide 2.4 mg at 14.2 per cent. Bottom row, Novo, one molecule, phase 2, 36 weeks: a single blue point for zenagamtide 40 mg at 14.6 per cent, marked as having no arm without amylin, because both actions are in the same molecule. The rows are not a ranking: the trials differ in length, stage and participants, and only the gap inside a row compares like with like.
@4040rec.bsky.socialSep 24, 2026, 8:52 AM

#Novo #obesity #patentprotection #Wegovy #weightloss #Ozempic #diabetes #CagriSema #Foundayo #Haematology #haemophiliaA #Frehemgo #sicklecelldisease #PNH #blooddisorders #endocrinedisorders #liverdiseases #cardiovasculardisease #consumerRx #pain #addiction #menshealth #womenshealth
zurl.co/Lmdba

@midgardfinance.comSep 22, 2026, 1:30 PM

💉 #obesity

🇩🇰 Novo Nordisk's #CagriSema beat 🇺🇸 Eli Lilly's tirzepatide in REIMAGINE 5: 12.4% against 9.1% weight loss at 60 weeks in type 2 diabetes.

At 1.0/1.0 mg, against tirzepatide's lowest 5 mg. The three head-to-heads fought at top dose all went to Lilly.

$NOVO $LLY

Horizontal bar chart of the four head-to-head trials that put a Novo Nordisk incretin against an Eli Lilly one, oldest readout at the top, weight loss at the primary endpoint on a scale from zero to about 34 per cent. Each trial has two bars, the Novo arm in blue above the Lilly arm in red, and each bar is labelled with the drug, its dose and its result. Each row also says whether the arms were at their top dose. SURMOUNT-5, obesity, 72 weeks, 2025, won by Lilly, both at top dose in 2025: semaglutide 2.4 mg 13.7 per cent against tirzepatide 15 mg 20.2 per cent. REDEFINE 4, obesity, 84 weeks, February 2026, won by Lilly, both at top dose: CagriSema 2.4/2.4 mg 23.0 per cent against tirzepatide 15 mg 25.5 per cent. ACHIEVE-3, type 2 diabetes, 52 weeks, March 2026, won by Lilly, both at top dose: oral semaglutide 14 mg 5.3 per cent against orforglipron 36 mg 8.2 per cent. REIMAGINE 5, type 2 diabetes, 60 weeks, September 2026, won by Novo, neither at top dose: CagriSema 1.0/1.0 mg 12.4 per cent against tirzepatide 5 mg 9.1 per cent, the only row where the blue bar is longer than the red one.
@recompsignal.comSep 21, 2026, 8:31 AM

CagriSema vs Zepbound is more than one percentage. Compare mechanisms, trial context, regulatory status—and what the head-to-head did not report. https://recompsignal.com/compare/?utm_source=bluesky&utm_medium=social&utm_campaign=video8 #CagriSema #Zepbound

@4040rec.bsky.socialSep 17, 2026, 8:33 AM

#NovoNordisk #Novo #weightloss #obesity #diabetes #TheNovoWay #GLP1agonists #semaglutide #Wegovy #Ozempic #oralWegovy #clinicaltrials #IL6inhibitor #ziltivekimab #heartfailure #atherosclerosis #CagriSema #cagrilintide #patentcliff #corporateculture #LastingHealthStartsNow
zurl.co/oizn3